How much profit has Geron made this year?
Geron has made -216.21 M USD this year.
Geron Net Income 2024
Geron Net Income
-216.21 M USD
Ticker
GERN
ISIN
US3741631036
WKN
902213
In 2024, Geron's profit amounted to -216.21 M USD, a 17.43% increase from the -184.13 M USD profit recorded in the previous year.
The Geron Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | 372.07 |
| 2028e | 278.3 |
| 2027e | 104.85 |
| 2026e | 53.58 |
| 2025e | -113.56 |
| 2024e | -216.21 |
| 2023 | -184.13 |
| 2022 | -141.9 |
| 2021 | -116.11 |
| 2020 | -75.62 |
| 2019 | -68.55 |
| 2018 | -27.02 |
| 2017 | -27.92 |
| 2016 | -29.54 |
| 2015 | 0.05 |
| 2014 | -35.67 |
| 2013 | -38.38 |
| 2012 | -68.88 |
| 2011 | -96.85 |
| 2010 | -111.38 |
| 2009 | -70.37 |
| 2008 | -62.02 |
| 2007 | -45.78 |
| 2006 | -31.37 |
| 2005 | -33.69 |
| 2004 | -79.56 |
Geron Revenue, EBIT, Net Income US3741631036 · 902213
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Geron, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Geron from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Geron’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Geron. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Geron’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Geron’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Geron’s growth potential.
Geron Revenue, EBIT and net profit per share
| Date | Geron Revenue | Geron EBIT | Geron Net Income |
|---|---|---|---|
| 2029e | 1.34 B undefined | 0 undefined | 372.07 M undefined |
| 2028e | 1.08 B undefined | 523.35 M undefined | 278.3 M undefined |
| 2027e | 725.94 M undefined | 265.6 M undefined | 104.85 M undefined |
| 2026e | 505.45 M undefined | 64.27 M undefined | 53.58 M undefined |
| 2025e | 258.36 M undefined | -127.74 M undefined | -113.56 M undefined |
| 2024e | 53.06 M undefined | -229.06 M undefined | -216.21 M undefined |
| 2023 | 237,000 undefined | -193.94 M undefined | -184.13 M undefined |
| 2022 | 600,000 undefined | -138.55 M undefined | -141.9 M undefined |
| 2021 | 1.39 M undefined | -114 M undefined | -116.11 M undefined |
| 2020 | 250,000 undefined | -76.91 M undefined | -75.62 M undefined |
| 2019 | 460,000 undefined | -72.51 M undefined | -68.55 M undefined |
| 2018 | 1.07 M undefined | -31.07 M undefined | -27.02 M undefined |
| 2017 | 1.07 M undefined | -29.26 M undefined | -27.92 M undefined |
| 2016 | 6.16 M undefined | -30.65 M undefined | -29.54 M undefined |
| 2015 | 36.37 M undefined | 750,000 undefined | 50,000 undefined |
| 2014 | 1.15 M undefined | -36.31 M undefined | -35.67 M undefined |
| 2013 | 1.28 M undefined | -37.5 M undefined | -38.38 M undefined |
| 2012 | 2.71 M undefined | -69.06 M undefined | -68.88 M undefined |
| 2011 | 2.44 M undefined | -90.67 M undefined | -96.85 M undefined |
| 2010 | 3.56 M undefined | -76.17 M undefined | -111.38 M undefined |
| 2009 | 1.73 M undefined | -70.23 M undefined | -70.37 M undefined |
| 2008 | 2.8 M undefined | -67.04 M undefined | -62.02 M undefined |
| 2007 | 7.62 M undefined | -62.84 M undefined | -45.78 M undefined |
| 2006 | 3.28 M undefined | -47.36 M undefined | -31.37 M undefined |
| 2005 | 6.16 M undefined | -37.71 M undefined | -33.69 M undefined |
| 2004 | 1.05 M undefined | -36.14 M undefined | -79.56 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 1.05 M USD | -36.14 M USD | -79.56 M USD |
| 2005 | 6.16 M USD | -37.71 M USD | -33.69 M USD |
| 2006 | 3.28 M USD | -47.36 M USD | -31.37 M USD |
| 2007 | 7.62 M USD | -62.84 M USD | -45.78 M USD |
| 2008 | 2.8 M USD | -67.04 M USD | -62.02 M USD |
| 2009 | 1.73 M USD | -70.23 M USD | -70.37 M USD |
| 2010 | 3.56 M USD | -76.17 M USD | -111.38 M USD |
| 2011 | 2.44 M USD | -90.67 M USD | -96.85 M USD |
| 2012 | 2.71 M USD | -69.06 M USD | -68.88 M USD |
| 2013 | 1.28 M USD | -37.5 M USD | -38.38 M USD |
| 2014 | 1.15 M USD | -36.31 M USD | -35.67 M USD |
| 2015 | 36.37 M USD | 750,000 USD | 50,000 USD |
| 2016 | 6.16 M USD | -30.65 M USD | -29.54 M USD |
| 2017 | 1.07 M USD | -29.26 M USD | -27.92 M USD |
| 2018 | 1.07 M USD | -31.07 M USD | -27.02 M USD |
| 2019 | 460,000 USD | -72.51 M USD | -68.55 M USD |
| 2020 | 250,000 USD | -76.91 M USD | -75.62 M USD |
| 2021 | 1.39 M USD | -114 M USD | -116.11 M USD |
| 2022 | 600,000 USD | -138.55 M USD | -141.9 M USD |
| 2023 | 237,000 USD | -193.94 M USD | -184.13 M USD |
| 2024e | 53.06 M USD | -229.06 M USD | -216.21 M USD |
| 2025e | 258.36 M USD | -127.74 M USD | -113.56 M USD |
| 2026e | 505.45 M USD | 64.27 M USD | 53.58 M USD |
| 2027e | 725.94 M USD | 265.6 M USD | 104.85 M USD |
| 2028e | 1.08 B USD | 523.35 M USD | 278.3 M USD |
| 2029e | 1.34 B USD | 0 USD | 372.07 M USD |
Geron stock margins US3741631036 · 902213
The Geron margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Geron. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Geron.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Geron's sales revenue. A higher gross margin percentage indicates that the Geron retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Geron's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Geron's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Geron's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Geron. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Geron's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Geron Margin History
| Geron Gross margin | Geron Profit margin | Geron EBIT margin | Geron Profit margin |
|---|---|---|---|
| 2029e | 0 % | 0 % | 27.68 % |
| 2028e | 0 % | 48.59 % | 25.84 % |
| 2027e | 0 % | 36.59 % | 14.44 % |
| 2026e | 0 % | 12.72 % | 10.6 % |
| 2025e | 0 % | -49.44 % | -43.96 % |
| 2024e | 0 % | -431.67 % | -407.46 % |
| 2023 | 0 % | -81,832.91 % | -77,690.72 % |
| 2022 | 0 % | -23,091.67 % | -23,650 % |
| 2021 | 0 % | -8,201.44 % | -8,353.24 % |
| 2020 | 0 % | -30,764 % | -30,248 % |
| 2019 | 0 % | -15,763.04 % | -14,902.17 % |
| 2018 | 0 % | -2,903.74 % | -2,525.23 % |
| 2017 | 0 % | -2,734.58 % | -2,609.35 % |
| 2016 | 0 % | -497.56 % | -479.55 % |
| 2015 | 0 % | 2.06 % | 0.14 % |
| 2014 | 0 % | -3,157.39 % | -3,101.74 % |
| 2013 | 0 % | -2,929.69 % | -2,998.44 % |
| 2012 | 0 % | -2,548.34 % | -2,541.7 % |
| 2011 | 0 % | -3,715.98 % | -3,969.26 % |
| 2010 | 0 % | -2,139.61 % | -3,128.65 % |
| 2009 | 0 % | -4,059.54 % | -4,067.63 % |
| 2008 | 0 % | -2,394.29 % | -2,215 % |
| 2007 | 0 % | -824.67 % | -600.79 % |
| 2006 | 0 % | -1,443.9 % | -956.4 % |
| 2005 | 0 % | -612.18 % | -546.92 % |
| 2004 | 0 % | -3,441.9 % | -7,577.14 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 0 % | -3,441.9 % | -7,577.14 % |
| 2005 | 0 % | -612.18 % | -546.92 % |
| 2006 | 0 % | -1,443.9 % | -956.4 % |
| 2007 | 0 % | -824.67 % | -600.79 % |
| 2008 | 0 % | -2,394.29 % | -2,215 % |
| 2009 | 0 % | -4,059.54 % | -4,067.63 % |
| 2010 | 0 % | -2,139.61 % | -3,128.65 % |
| 2011 | 0 % | -3,715.98 % | -3,969.26 % |
| 2012 | 0 % | -2,548.34 % | -2,541.7 % |
| 2013 | 0 % | -2,929.69 % | -2,998.44 % |
| 2014 | 0 % | -3,157.39 % | -3,101.74 % |
| 2015 | 0 % | 2.06 % | 0.14 % |
| 2016 | 0 % | -497.56 % | -479.55 % |
| 2017 | 0 % | -2,734.58 % | -2,609.35 % |
| 2018 | 0 % | -2,903.74 % | -2,525.23 % |
| 2019 | 0 % | -15,763.04 % | -14,902.17 % |
| 2020 | 0 % | -30,764 % | -30,248 % |
| 2021 | 0 % | -8,201.44 % | -8,353.24 % |
| 2022 | 0 % | -23,091.67 % | -23,650 % |
| 2023 | 0 % | -81,832.91 % | -77,690.72 % |
| 2024e | 0 % | -431.67 % | -407.46 % |
| 2025e | 0 % | -49.44 % | -43.96 % |
| 2026e | 0 % | 12.72 % | 10.6 % |
| 2027e | 0 % | 36.59 % | 14.44 % |
| 2028e | 0 % | 48.59 % | 25.84 % |
| 2029e | 0 % | 0 % | 27.68 % |
Geron Aktienanalyse
What does Geron do?
Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Geron's Profit Margins
The profit margins of Geron represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Geron's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Geron's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Geron's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Geron’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Geron stock
How has the profit developed compared to last year?
The profit has increased by 17.43% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Geron publish its earnings?
Geron publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Geron?
The profits of Geron are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Geron?
You can learn more about the earnings of Geron by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Geron pay?
Over the past 12 months, Geron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Geron is expected to pay a dividend of 0 USD.
What is the dividend yield of Geron?
The current dividend yield of Geron is .
When does Geron pay dividends?
Geron pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Geron?
Geron paid dividends every year for the past 0 years.
What is the dividend of Geron?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Geron located?
Geron is assigned to the 'Health' sector.
Wann musste ich die Aktien von Geron kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Geron from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.
When did Geron pay the last dividend?
The last dividend was paid out on 7/16/2024.
What was the dividend of Geron in the year 2023?
In the year 2023, Geron distributed 0 USD as dividends.
In which currency does Geron pay out the dividend?
The dividends of Geron are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Geron stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Geron
Our stock analysis for Geron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Geron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
